突变型p53与其合成致死基因的研究进展  

Synthetic lethal genes to mutant p53

作　　者：刘同阳 郭海强[2] 朱美妍[2] 黄英泽[2] 贾舒婷[2] 罗瑛[2] 张继虹[2] 

机构地区：[1]昆明理工大学生命科学与技术学院,昆明650500 [2]昆明理工大学医学院,衰老与肿瘤分子遗传学实验室,昆明650500

出　　处：《遗传》2015年第4期321-326,共6页Hereditas（Beijing)

基　　金：国家自然科学基金项目(编号:81260501;U1202221)资助

摘　　要：恶性肿瘤的靶向治疗已经成为现阶段肿瘤治疗的热点。随着人们对癌基因认知的加深,借助合成致死的方法靶向治疗肿瘤已成为针对肿瘤特异性治疗的新策略。p53基因突变在肿瘤的形成和发展过程中具有重要作用。因此,了解肿瘤中与突变型p53基因有合成致死关系的靶基因的作用方式,有助于指导由突变型p53基因诱发肿瘤的个性化治疗。与突变型p53基因具有合成致死关系的靶基因可分为细胞周期调控基因和细胞非周期调控基因,文章综述了这两类靶基因与突变型p53基因如何构成合成致死作用以及此作用的现实意义。Targeted therapy has become a powerful approach for cancer treatment. Better understanding of onco-genes as well as synthetic lethal interactions with oncogenes will lead to new strategies for tumor-specific treatment. It is well known that mutant p53 plays an important role in tumorigenesis and tumor development. Thus, understand-ing the synthetic lethal relationship between p53 mutations and interacting genes in tumor is critical for the personal-ized treatments of p53 mutant tumors. Synthetic lethal genes to mutant p53 can be divided into cell cycle regulators and non-cell cycle regulators. This paper review show these two types of target genes contribute to synthetic lethal interactions with p53 mutations and potential applications of these interactions in anticancer therapy.

关 键 词：P53 合成致死 合成致死的交互作用 肿瘤 P53 

分 类 号：R730.5[医药卫生—肿瘤]